Introduction
Metabolic syndrome is caused by overeating (the excessive continuous ingestion of carbohydrate and lipid), and obesity (resulting from low physical activity and/or energy consumption).
Particularly, it is generally accepted that increasing intake of saturated fatty acids and animal proteins and decreasing intake of dietary fiber and vegetable protein contribute to the development of metabolic syndrome (Matsuzawa 2005) . The core clinical component of the syndrome is visceral fat (i.e., the accumulation of fat in adipose depots around the organs of the peritoneal cavity), whereas the principal metabolic abnormality is insulin resistance (Matsuzawa 1997 and 2006) . Locomotive syndrome refers to the functional decline of locomotive organs with aging due to muscle weakness, arthritis, and osteoporosis; locomotive syndrome is a major factor of "shortening of a healthy life" and "bedridden and need of long-term care."
Metabolic syndrome and locomotive syndrome will not only reduce the quality of life (QOL) for affected people but also bear the financial burden. Medical expenses in Japan continue to increase, with annual national health expenditures of more than 40 trillion yen and 321,100 yen per person (Ministry of Health, Labour and Welfare, 2016, Fig. 1) . Improving citizen awareness to prevention and/or treatment of metabolic syndrome and locomotive syndrome is thought to be important for improving QOL for individuals and reducing medical expenses.
Soy protein exerts not only conventional nutritional value but also beneficial effects on human health. Particularly, soy protein has been reported to help prevent metabolic syndrome and improve various pathological conditions associated with metabolic syndrome (Anderson et al., 1995; Zhan and Ho, 2005; Sirtori et al., 2007) . The US Food and Drug Administration (FDA) has approved for food labeling the health claim that the consumption of 25 g soy protein per day reduces the risk of heart disease (Food and Drug Administration. 1999) . In Japan, the Consumer Affairs Agency (formerly Ministry of Health, Labour and Welfare) has allowed the health labeling of soy protein as a food for specified health use "to people who are concerned about cholesterol level" (FOSHU, http:// www.caa.go.jp/foods/index4.html#m02).
Soy peptide, "Hinute AM" is a food ingredient that was developed with the objective of high absorption of amino acids.
Proteins have been thought to be digested (hydrolyzed) by the stomach and intestines and then absorbed as individual amino acids. However, subsequent studies have also revealed the presence of a peptide transporter (Shimizu and Son 2007) . In order to increase protein absorptivity, it is better to hydrolyze proteins into a mixture of amino acids and di-and/or tri-peptides before consumption. Dipeptides, tripeptides, and free amino acids account for 60% or more of the total nitrogen in Hinute AM, and the high amino acid absorption efficiency of Hinute AM has been clinically studied . Many beneficial effects of Hinute AM on human health have been reported (Masuda et al., 2007; Matsushita et al., 2012; de Oliveira et al., 2015; Imai et al., 2017) .
In this review, the author introduces soy protein and soy peptide as complementation medical food materials for the prevention of metabolic syndrome and locomotive syndrome, as well as for improving dyslipidemia and rheumatoid arthritis symptoms. There are known serious side effects from statins, including muscle symptoms, rhabdomyolysis (secondary renal failure due to destruction of specific muscle tissue), peripheral neuropathy, myopathy, liver dysfunction, and thrombocytopenia (Laufs et al., 2015; Kwak 2014; Lei et al., 2014; Haque et al., 2016) .
Rhabdomyolysis often induces sudden kidney failure (Ambapkar et al., 2016). Accordingly, it is necessary to carefully consider the pharmacokinetics of myogenic enzymes such as creatinine phosphokinase (CPK) and myoglobin at the time of administration of statin. Fibrate-related side effects include the development of slight gastric region discomfort and myopathy (myalgia with the increased CPK). Because fibrates increase cholesterol in the bile duct, the risk of gallstones increases. When statins and fibrates are used in combination, the risk of rhabdomyolysis is reported to rise.
Combinations of these two agents are, in principle, contraindicated.
Soy protein lowers serum cholesterol levels by acting as a bile acid sequestrant, which binds bile in the gastrointestinal tract to prevent its reabsorption by performing the same anion exchange reaction as the resin cholestyramine (Nakamura and Matsuzawa, 1994) . Soy protein removes bile acids from the body by forming insoluble complexes with bile acids in the intestine, which are then excreted in the feces. The loss of bile acids results in higher levels of cholesterol transport into hepatocytes for conversion to bile acids. Consequently, serum cholesterol levels are normalized (Sugano et al., 1988 and 1990, Fig. 2) . The mechanism by which soy protein lowers cholesterol differs from that of statins.
Accordingly, statin and soy protein are expected to act additively or synergistically to decrease cholesterol levels.
In this review, the author introduces the potential beneficial effect of a soy protein-based snack (low-energy, high-protein, lowcarbohydrate, and very low-fat) on dyslipidemia (Nabiki et al., 2016) . Moreover, we show an improvement in diabetic nephropathy with a soy protein snack and an effect on chronic kidney disease with soy protein β-conglycinin complementation.
Soy protein for dyslipidemia
The Japan Society for the Study of Obesity defines obese individuals as those with a body mass index (BMI) of 25 kg/m 2 or higher (Examination committee of criteria for "Obesity diseases' in Japan 2002). Nabiki et al. (2016) examined the effects of a soy protein snack on weight loss, markers of diabetes, and parameters of dyslipidemia in obese diabetic patients with high levels of LDL-cholesterol and triglyceride who were treated with statins and/or fibrates (Table 1 , protocol 1). In this study, there were 28 hyperlipidemic patients who did not have an adequate improvement in blood lipids even after continuous ingestion of the lipid-improving drugs (fibrates, 24 patients; statins, two patients; both drugs concomitant medication, two patients).
These participants consumed a soy protein snack containing 6.8 g of soy protein (total 17.6 g and 62.4 kcal) per day along with the lipid-improving drugs. They were also instructed to consume 300 mg or less of cholesterol, 50 g or less of fat, and to eat fish products rather than meat products. As a result, these patients experienced a significant decrease in body weight of about 1 kg and a significant decrease in waist circumference of about 2 cm. Total cholesterol, triglyceride, LDL-cholesterol, apolipoprotein B, and glycated hemoglobin levels decreased significantly, and HDLcholesterol level increased significantly (Fig. 3) . In addition, a lipid metabolism-improving effect was also observed in patients who did not lose weight, and this effect was suggested to be a direct effect of soy protein. Therefore, the use of soy protein may help to reduce the drug dose for dyslipidemia (Nabiki et al., 2016) .
The author introduces the follow-up result of one of the 28 patients in the above study (Nabiki et al., 2016) in whom triglyceride and total cholesterol levels were reduced following consumption of soy protein snacks (Fig. 4) either drug therapy.
Soy protein for diabetic nephropathy Metabolic syndrome and nephropathy are closely related; in particular, nephropathy is a complication of diabetes. Moreover, 40% of patients undergoing dialysis are reported to have diabetic nephropathy (Yokoyama et al., 2007) . Furthermore, about 50% of type II diabetes patients exhibit urinary albumin disease, which is an early stage of diabetic nephropathy (Parving et al., 2006) . TG, triglyceride; LDL-C, LDL-cholesterol; HDL-C, HDL-cholesterol, TC, total-cholesterol; FPG; fasting plasma glucose; ALB/Cre, urinary albumin to creatinine ratio; TP, total protein; Cr, creatinine; UA, uric acid; VAS, visual analog score; DAS28, disease activity score 28; CDAI, clinical disease activity index; TNF-α, tumor necrosis factor-α; IL-1β, interleukin-1β; IL-6, interleukine-6; CRP, C-reactive protein; MMP-3, matrix metalloprotease-3; ESR, erythrocyte sedimentation rate. *, 8 weeks consumption period and 4 weeks post evaluation phase. The results are expressed as means ± SD. * and **: significantly different from placebo group (*p < 0.05 and **p < 0.01).
2012; Jheng et al., 2016) . The urine test of diabetic patients in the above-mentioned study (Nabiki et al., 2016) revealed that there were several subjects with high urine albumin levels. These patients have been administered therapeutic agents for treatment of diabetes (sulfonylureas, biguanides, DPP-4 inhibitors and α-glucosidase inhibitors) and dyslipidemia (statins and fibrates).
The urinary albumin level decreased by taking soy protein snack, and the improvement on dyslipidemia was also observed (Table 2) . Fig. 5 ). β-conglycinin has been reported to decrease serum triglyceride levels and visceral fat by inhibiting hepatic fatty acid synthesis (Kohno et al., 2006 and Ohara et al., 2006; Hori et al., 2009) ; in addition, β-conglycinin improves insulin sensitivity and lowers triglyceride levels in hypertriglyceridemia (Moriyama et al., 2004; Fukui et al., 2004; Tachibana et al., 2010 Clinical characteristics of subject Male, age 64, height 161 cm, weight 64 kg (BMI=24.6) Diagnosis; Type 2 diabetes and diabetic copplication (second stage of nepropathy; eGFR 75.1 mL/min/1.73 m 2 ) during medication for diabetes PPG, postprandial plasma glucose level; TG, triglyceride, LDL-C, LDL-cholesterol; HDL-C, HDL-cholesterol, ALB/Cre, urinary albumin to creatinine ratio et Rughooputh et al., 2015) . Therefore, it is necessary to consider not only the quantity but also the quality of protein. Soy protein can be regarded as very significant protein to help treat nephropathy.
Soy protein for chronic kidney disease

Complementary effect of soy peptide on locomotive syndrome due to rheumatoid arthritis
Background Rheumatoid arthritis is due to inflammation triggered by an immune response to autoantigens. There are 700,000-800,000 patients with rheumatoid arthritis, about 10 million patients with osteoporosis, and close to 700,000-10 million patients with osteoarthritis in Japan (Yoshimura et al., 2009) 
Soy peptide as an anti-inflammatory agent In elderly patients undergoing rehabilitation after a fall, ingestion of the soy peptide
Hinute AM significantly increased muscle mass compared to those who only underwent rehabilitation exercise (Shinkai et al., 2009 , Table 1 , protocol 3). Interestingly, in this study, in the group who ingested the Hinute AM during rehabilitation exercise, the total white blood cells decreased significantly more than that in the group with only rehabilitation exercise. Total white blood cells increased at the final stage of the inflammatory cascade and is therefore a marker reflecting the inflammatory burden in the body (Pearson et al., 2003) . This inflammatory response was suggested to be suppressed by ingesting Hinute AM during rehabilitation exercise. Moreover, an in vitro study using macrophages revealed that Hinute AM inhibited inflammation. In this review, the author introduces the role of Hinute AM as a complementary medicine for the treatment of rheumatoid arthritis (Yoshioka et al., 2015, Table   1 , protocol 4).
Soy peptide for rheumatoid arthritis
In a double-blind, randomized, parallel-group study for outpatients with rheumatoid arthritis, one group of subjects consumed Hinute AM and the other consumed a placebo. Blood levels of the cartilage matrix degrading enzyme matrix metalloproteinase 3 (MMP-3) and inflammatory cytokines such as IL-1β and IL-6 were measured. The Disease Activity Score 28 (DAS 28, an assessment used by clinicians to measure the disease activity of rheumatoid arthritis) and the Clinical Disease Activity Index (CDAI, an index that measures changes in the disease activity of rheumatoid arthritis) were calculated from the improvement degree of ADL, the severity of pain, and subjective symptoms (visual analog scale, VAS).
The pain score, the physician's assessment of disease activity on a VAS, and the CDAI (which reflects the physician's assessment of disease activity on a VAS) decreased when consuming Hinute The black circle shows TG, and the black square shows LDL-C. B: Changes for 3 months in estimated glomerular filtration rate (eGFR) and blood urea nitrogen/ creatinine ratio (BUN/Cre). The black circle shows eGFR, and the black square shows BUN/Cre. The results are expressed as means ± SD. *, significant difference between before and after of β-conglycinin consumption (p < 0.05).
AM. The patient VAS score and DAS28-CRP score tended to decrease markedly, and the peptide group had a significantly lower patient VAS score than that in the placebo group. The Hinute AM group had significantly lower levels of IL-6 and IL-1β than those in the placebo group (Fig. 6 ).
IL-6 and IL-1β are closely associated with the pathology of rheumatoid arthritis. The antibody pharmaceutical products (anticytokine antibodies) are intended to limit levels of in the body (Kaneko and Takeuchi 2014; Gibofsky 2014 ). IL-6 induces antibody production, causing hypergammaglobulinemia and the emergence of rheumatoid factors (Scholes and Smolen 2012) . IL-6 is also a hepatocyte-stimulating factor and increases C-reactive protein and serum amyloid A, which causes secondary amyloidosis (Firestein 2003) . In addition, IL-6 activates osteoclasts, induces bone resorption and destruction, and increases joint destruction. Moreover, an increase in blood IL-6 levels is associated with extra-articular symptoms of rheumatoid arthritis such as general malaise, loss of appetite, weight loss, and a slight fever. Consumption of soy peptide decreases IL-6 level. According to the Japan SPF Swine Society, causes of ulcers in the gastroesophageal region of pigs are defined to be similar to those in humans. Pigs are monogastric and omnivorous animals, so their digestive physiology and intestinal flora are similar to those in humans. The etiology of an enteric infection with a virus or Escherichia coli in neonates is similar to that in piglets, so pigs are a useful model of disease (Miller and Ullrey 1987) . The use of dextran sulfate sodium (DSS)-induced colitis has been used as a model of ulcerative colitis (Poritz et al., 2007) .
In a study by Young et al. using 5-7-day-old Yorkshire pigs, one group was given a normal saline solution, and two groups were given a normal saline solution containing DSS. Afterwards, the group receiving DSS was given Hinute AM. The other group that was given DSS and the group that was given normal saline were both given a normal saline solution containing alanine to match nitrogen in the soy peptide. The group receiving soy peptide showed almost the same pathology findings compared to that in the group not receiving DSS. Moreover, the expression of genes encoding inflammatory cytokines and protein production of the soy peptide group were also the same compared to that of the no-DSS group (Young et al., 2012) . Moreover, Kovacs-Nolan et al. reported that the soy-derived tripeptide Val-Pro-Tyr (VPY) has anti-inflammatory effects in Caco-2 and THP-1 macrophages (in vitro study). They showed that VPY inhibited the secretion of IL-8 and TNF-α in a mouse model of DSS-induced colitis (in vivo study, Kovacs-Nolan et al. 2012) . They suggested that tripeptide VPY from soy peptide may be promising for the treatment of IBD. 
Conclusion
